{
    "nctId": "NCT00258349",
    "briefTitle": "Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer",
    "officialTitle": "A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No active or ongoing infection\n* No history of allergic reaction to compounds of similar chemical or biologic composition to vorinostat or other agents used in study\n* No psychiatric illness or social situation that would preclude study compliance\n* No other uncontrolled illness\n* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin; 1 week for capecitabine) and recovered\n* More than 3 weeks since prior radiotherapy and recovered\n* Recovered from prior therapy\n* At least 2 weeks since prior valproic acid\n* More than 4 weeks since prior investigational agents\n* More than 4 weeks since prior lapatinib ditosylate\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* Measurable disease, defined as \\>= 1 unidimensionally measurable lesion \\> 20 mm by conventional techniques or \\> 10 mm by spiral CT scan\n* No other concurrent investigational agents\n* Concurrent bisphosphonates allowed provided therapy was initiated prior to study treatment\n* No other concurrent anticancer therapy\n* Recurrent or progressive disease while receiving prior trastuzumab (Herceptin) (with or without chemotherapy) OR relapsed within 3 months of last dose of prior adjuvant trastuzumab for metastatic disease\n* Histologically confirmed breast cancer\n* Must overexpress HER-2 gene\n* Metastatic or chest wall recurrent disease\n* Site of measurable disease must not have been irradiated (except chest wall recurrence treated with adjuvant radiation therapy)\n* No untreated brain metastases\n* Previously treated brain metastasis responsive to radiotherapy and/or surgery allowed provided the brain is not the sole site of measurable disease\n* ECOG 0-2\n* Absolute neutrophil count \\>= 1,500/mm\\^3\n* Platelet count \\>= 100,000/mm\\^3\n* Hemoglobin \\>= 9 g/dL\n* AST and ALT =\\< 2 times upper limit of normal\n* Bilirubin =\\< 1.5 mg/dL (3 mg/dL in the presence of Gilbert's disease provided direct bilirubin is normal)\n* Creatinine =\\< 1.5 mg/dL\n* LVEF normal by nuclear scan or echocardiogram\n* No evidence of PR prolongation or AV block by EKG\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}